Beeline Holdings Inc. (NASDAQ: BLNE)

The QualityStocks Daily Newsletter would like to spotlight Beeline Holdings Inc. (NASDAQ: BLNE).

Beeline (NASDAQ: BLNE) , a rapidly growing fintech company, was highlighted by Streetwise Reports in a Feb. 27, 2026 article examining the Company’s accelerating revenue trajectory and market positioning within the U.S. mortgage sector. According to Streetwise Reports, Beeline owns 100% of an independent mortgage banker, a title company and a B2B SaaS products company, along with a minority stake in an AI sales tools firm. Its flagship AI-enabled, digital end-to-end financing platform delivers debt and equity solutions to homeowners and property investors more seamlessly and cost-effectively. With more than $1 billion in cumulative loan originations, Beeline is targeting the expansive U.S. mortgage market through AI-driven lead generation and conversion. Its product suite includes Beeline Loans for fully digital mortgage originations, Beeline Title for streamlined in-house title services, a B2B SaaS audit tool designed to meet lender compliance requirements and Beeline Equity, a fractional equity product positioned as an alternative to HELOCs and other traditional financing solutions.

About Beeline Financial Holdings Inc.

Beeline Financial Holdings, Inc. is a trailblazing mortgage fintech transforming the way people access property financing. Through its fully digital, AI-powered platform, Beeline delivers a faster, smarter path to home loans—whether for primary residences or investment properties. Headquartered in Providence, Rhode Island, Beeline is reshaping mortgage origination with speed, simplicity, and transparency at its core. The company is a wholly owned subsidiary of Beeline Holdings, Inc. and also operates Beeline Labs, its innovation arm focused on next-generation lending solutions.

For more, visit www.makeabeeline.com

Beeline Holdings Inc. (NASDAQ: BLNE) is a technology-forward mortgage and title platform leveraging AI, automation, and intuitive user experiences to simplify home financing. Through wholly owned subsidiary Beeline Loans Inc., the company delivers fast and flexible loan solutions for both primary homebuyers and real estate investors. Beeline has built an end-to-end digital lending ecosystem designed to eliminate friction, reduce costs, and dramatically shorten closing timelines.

Since completing its October 2024 merger with Eastside Distilling, Beeline has solidified its position as a next generation fintech mortgage originator. Its core vision centers on digitizing the mortgage journey with tools like AI chatbot Bob, proprietary production engine Hive, and an expanding SaaS product suite. These innovations enable Beeline to close loans in just 14–21 days—less than half the industry average—while achieving a Net Promoter Score above 80, more than four times higher than the sector benchmark.

Beeline’s mission is to make home loans effortless by giving users instant access to rate quotes, approvals, and document uploads—all online, 24/7. Having surpassed $1 billion in cumulative loan originations and achieved 38% year-over-year growth, Beeline is scaling its platform across the U.S. mortgage and real estate investing landscape.

The company is headquartered in Providence, Rhode Island.

Products

Beeline operates a fully digital, AI-enabled loan origination and title ecosystem. Key features include:

• Bob 2.0 – The industry’s first AI mortgage agent, available 24/7/365 to quote rates and pre-approve borrowers; Bob has delivered 6x lead conversion and 8x full application volume compared to traditional loan officers.
• Hive – A task-based processing engine that replaces manual workflows with scalable automation, cutting loan closing times to as little as 14 days.
• BlinkQC – Beeline’s proprietary AI quality control platform that replaces costly third-party reviews.
• Beeline Title – A fully diversified title services unit supporting digital collateral transfer, remote closings, and investor-focused solutions.
• MagicBlocks – A customizable AI sales agent platform developed by Beeline and spun out into its own entity; Beeline retains equity and licensing rights, positioning it to benefit from future growth and deployment of the technology.

The company also provides Debt Service Coverage Ratio (DSCR), bank statement, and conventional mortgage products tailored to investors, including short-term rental operators. Strategic partnerships with Rabbu and Red Awning streamline property analysis, financing, and management within a single ecosystem.

Market Opportunity

The U.S. mortgage market is poised for growth in 2025, with total mortgage origination volume expected to increase by 28% to $2.3 trillion, up from $1.79 trillion in 2024. This projection includes a 13% rise in purchase originations to $1.46 trillion.

Within this expanding market, investor lending, particularly through DSCR loans, represents a rapidly growing segment. DSCR loans, which are underwritten based on the income generated by the property rather than the borrower’s personal income, are ideal for real estate investors, particularly those purchasing long-term or short-term rental properties. Beeline has strategically positioned itself in this niche, with over one-third of its volume derived from DSCR products. Through its affiliate referral network and integrations with platforms like Rabbu, the company is actively expanding its market reach in this high-margin category.

Non-agency mortgage issuance, which includes DSCR loans, is projected to reach $160 billion in 2025, a 16% increase from 2024.

Leadership Team

Nick Liuzza, Chief Executive Officer, co-founded Beeline Mortgage LLC in 2019 after selling Linear Title & Closing and Linear Settlement Services to Real Matters. He also previously built New Age Nurses into a national staffing firm. He currently serves as EVP of Real Matters (TSX: REAL).

Jess Kennedy, Chief Operating Officer, is a co-founder of Beeline with 15 years of legal and real estate experience. She previously served as General Counsel and Chief Compliance Officer at Beeline and held roles at Solidifi, LeClairRyan, and Edwards Wildman Palmer LLP, handling complex real estate finance and title transactions.

Chris Moe, Chief Financial Officer, joined Beeline in 2023 with over 40 years of finance and investment banking experience. He has held senior roles at Red Cat Holdings (NASDAQ: RCAT), IRIS Therapeutic Devices, and Yates Electrospace Corporation, bringing deep public company and defense sector expertise.

Beeline Holdings Inc. (NASDAQ: BLNE), closed Monday's trading session at $2.96, up 5.7143%, on 492,062 volume. The average volume for the last 3 months is 774,079 and the stock's 52-week low/high is $0.6202/$7.9471.

Recent News

• Beeline Holdings Inc. (NASDAQ: BLNE) - MissionIRNewsBreaks - Beeline Holdings Inc. (NASDAQ: BLNE) Featured by Streetwise Reports for Rapid Revenue Growth and Fintech Expansion
• AINewsBreaks - Beeline Holdings Inc. (NASDAQ: BLNE) Highlights Gains, Sets Course for Next Phase of Growth
• MissionIRNewsBreaks - Beeline Holdings, Inc. (NASDAQ: BLNE) Appoints Barry Levenson as Executive Strategic Advisor

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system, announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Dr. Kelley brings more than 20 years of global leadership experience spanning clinical development, translational medicine and regulatory strategy across oncology, rare diseases, CNS and medical devices, having led Phase 1–3 programs and supported regulatory approvals in the United States, Europe, China and Japan. She has previously served as chief medical officer at several biotechnology and medical device companies, including TISSIUM, Servier Pharmaceuticals, X4 Pharmaceuticals and Senseonics, and held senior leadership roles at Boston Scientific and Becton Dickinson. The Company said Dr. Kelley’s expertise in advancing clinical programs and executing regulatory strategy will support pipeline prioritization and long-term growth initiatives.

To view the full press release, visit https://ibn.fm/T52Ad

A new study may have just given brain surgeons a significantly better way to fight cancer without compromising how patients live afterward. Published in Science Advances, the research unlocks a layer of information already sitting in the operating room, one that surgeons have never had the tools to interpret until now. Awake brain mapping has anchored neurosurgical practice for generations. The procedure keeps patients conscious while surgeons deliver precise electrical pulses to targeted brain regions, monitoring responses to verbal tasks as they operate. Accurate, timely answers indicate a region is safe to remove, while hesitation or speech failure signals the opposite, and because the brain carries no pain-sensing nerves, patients feel none of it. University of Rochester neurosurgeon Tyler Schmidt has used MindTrace in over ten operations this year and says it gives his team a coherent, real-time picture that sharpens decision-making at every stage. Schmidt says the ambitions of brain tumor surgery have been genuinely transformed. Where surgeons once asked simply whether safe removal was possible at all, the question has become which specific capacities matter most to each patient, and how to preserve them while reaching the same medical destination. That shift, he says, represents a fundamentally better standard of care. Once surgery is successfully completed using this brain mapping approach, medications like those being developed by pharmaceutical companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) can then treat any residual cancer tissues. 

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $3.13, up 0.6430868%, on 7,457 volume. The average volume for the last 3 months is 20,812 and the stock's 52-week low/high is $2.94/$55.2.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - New Study Unveils Promising Way to Conduct Brain Surgery Against Cancer
• TinyGemsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer
• American Science Suffers as Brain Drain Intensifies

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

China has officially made its first domestically developed quantum computing operating system available for public download. The system, called Origin Pilot, represents a significant milestone in the country’s push to expand its capabilities in advanced computing technologies. The operating system was created by Origin Quantum Computing Technology Co., a firm based in Hefei that also developed China’s third-generation superconducting quantum computer, Origin Wukong. Although Origin Pilot was first introduced in 2021, it has undergone several rounds of improvement and testing before being released for wider public use. This move also fits into China’s broader national strategy to strengthen innovation and reduce dependence on foreign technology. Quantum computing has been identified as a priority industry for future development. As part of long-term economic planning, the country is investing heavily in emerging fields such as artificial intelligence, advanced communications, and clean energy technologies. The release of Origin Pilot suggests that China’s quantum sector is progressing from experimental research toward practical deployment. By opening its operating system to the public, the country hopes to build a stronger ecosystem around quantum computing and support the growth of new applications in science, industry, and technology. With this release, American firms like D-Wave Quantum Inc. (NYSE: QBTS) focused on developing quantum computing solutions could face stiff competition from China-based competitors. 

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Monday's trading session at $18.94, up 0.8519702%, on 18,583,445 volume. The average volume for the last 3 months is 28,015,735 and the stock's 52-week low/high is $4.45/$46.75.

Recent News

• D-Wave Quantum Inc. (NYSE: QBTS) - World Leaders Attend AI Impact Summit Hosted by India
• TechMediaBreaks - D-Wave Quantum Inc. (NYSE: QBTS) Joins Southeastern Quantum Collaborative as Inaugural Member
• Investors Sell Stocks as Worries Over AI Disruption Spread

Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF)

The QualityStocks Daily Newsletter would like to spotlight Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF).

This article has been disseminated on behalf of Fairchild Gold Corp. and may include paid advertising.

Fairchild Gold (TSX-V: FAIR; OTCQB: FCHDF; Frankfurt: Y4Y) announced it has expanded its Nevada Titan Property in southwestern Nevada through additional claim staking, increasing the total land position to approximately 25.3 square kilometers, or 6,251.7 acres. The newly staked ground is contiguous with the Company’s existing holdings and enhances coverage over geological and geophysical features aligned with its exploration targets. Fairchild has also engaged KLM Geoscience to conduct a Controlled Source Audio-frequency Magnetotellurics survey to evaluate subsurface resistivity and refine three high-priority magnetic targets associated with potential porphyry copper-gold and high-grade vein-type copper-gold-silver-cobalt-antimony systems. Fieldwork began Feb. 25, 2026, and is expected to continue for approximately two weeks, with results to be integrated alongside prior magnetic and induced polarization data to support future exploration planning.

To view the press release, visit https://ibn.fm/nVZQ2

Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF) is a mineral exploration company focused on acquiring, exploring, and developing high-quality mineral properties in mining-friendly jurisdictions across North America. The company targets projects with historical production, strong multi-metal potential, and clear pathways to discovery through modern geoscience, AI integration, and responsible development practices.

Fairchild’s portfolio is anchored by the Nevada Titan Project, a district-scale, copper-gold system located just outside Las Vegas in the prolific Walker Lane Belt. The company has also entered into an MOU to acquire the advanced-stage Golden Arrow Project in Nevada, subject to completion of a definitive agreement, and it holds 100% ownership of the Fairchild Lake Property in Ontario.

Fairchild’s mission is to build long-term value by identifying overlooked mineralized systems and unlocking their potential using modern exploration methods.

The company is headquartered in Vancouver, British Columbia.

Projects

Nevada Titan Project (Goodsprings District, Nevada)

Nevada Titan is Fairchild’s flagship asset and a district-scale, multi-metal opportunity located just 55 kilometers southwest of Las Vegas. Spanning over 6,150 acres (300+ claims), the project sits within the historically productive Goodsprings Mining District—part of the prolific Walker Lane Belt and Battle Mountain Trend extension. The area hosts numerous historic mines, including Copperside, Copper Chief, Azurite, and Fitzhugh Lee, yet remains largely untested by modern drilling.

Surface sampling and geological mapping have confirmed high-grade copper mineralization up to 34.0% Cu, with associated values of gold, silver, molybdenum, and platinum group elements. A 1.5-kilometer copper-gold corridor has been identified, showing pods and lenses of mineralization consistent with a porphyry-skarn-CRD system. Notably, the discovery of a hydrothermal breccia pipe with garnet-bearing skarn textures and elevated molybdenum signals a porphyry-affiliated source at depth.

Ongoing exploration includes drone magnetics, AI-integrated targeting, and induced polarization geophysics. With infrastructure already in place and proximity to Las Vegas contractors, Fairchild is preparing for a 2026 drill campaign focused on unlocking the project’s large-scale copper-gold system.

Golden Arrow Project (Walker Lane Shear Zone, Nevada)

In September 2025, Fairchild signed a Memorandum of Understanding to acquire 100% of the Golden Arrow Project, an advanced-stage gold-silver asset in Nevada’s Walker Lane Trend. The project hosts a historic mineral resource estimate of approximately 347,000 ounces of gold and 5.3 million ounces of silver, including 296,500 ounces of gold and 4.0 million ounces of silver in the measured and indicated categories. According to third-party analysis by mining analyst Ryan D. Long, the total acquisition consideration of $5.0 million equates to approximately $12 per ounce of gold in the ground.

The project’s two main deposits, Gold Coin and Hidden Hill, were historically mined at surface and remain open at depth, supported by over 61,000 meters of past drilling. Modern geophysical work has outlined 34 additional exploration targets, including six classified as high-priority. Hosted in a volcanic complex with both high-grade vein and disseminated mineralization, the system offers strong potential for expansion.

Golden Arrow is situated just 96 kilometers from Kinross’s 28-million-ounce Round Mountain Mine and expands Fairchild’s Nevada footprint by 170% when combined with the Titan Project. The project’s extensive exploration database and near-surface deposits make the acquisition a compelling strategic entry point into a proven district with significant near-term development potential.

Fairchild Lake Property (Savant Lake Greenstone Belt, Ontario)

Fairchild Gold holds 100% ownership of the Fairchild Lake Property, a 2,224-hectare claim package in Ontario’s underexplored Savant Lake greenstone belt. Historical and recent work, including airborne geophysics and soil sampling, has identified anomalous gold values near the Kashaweogama Lake Fault, a major crustal break. The company draws geological comparisons to Red Lake’s LP Fault and views the structural setting as a promising focus for future exploration.

Market Opportunity

Fairchild operates in Tier-1 mining jurisdictions where political stability, established infrastructure, and clear permitting pathways reduce development risk and enhance long-term value. Nevada, in particular, is a top-ranked global destination for mineral exploration and home to some of the world’s most productive gold and copper belts. Fairchild’s flagship project, Nevada Titan, is located in the Walker Lane Belt, a prolific trend responsible for more than 89 million ounces of gold and nearly 1 billion ounces of silver to date.

The company is strongly positioned to benefit from the ongoing historic bull market in gold. In early October 2025, Goldman Sachs raised its December 2026 gold price forecast to $4,900 per ounce, citing strong ETF inflows and sustained central bank demand. A Jefferies analyst has projected gold could reach $6,600 per ounce in the near term, while other major institutions including UBS and Bank of America have also raised their targets amid elevated geopolitical risk, structural reserve diversification, and anticipated U.S. rate cuts. With limited new supply and rising demand from both institutional and retail investors, gold remains a cornerstone of portfolio hedging and upside exposure.

Copper also remains a core strategic focus, with demand expected to double by 2035, driven by electrification, grid modernization, and clean energy buildout, according to S&P Global. The Nevada Titan Project hosts porphyry-style copper-gold mineralization, along with skarn and carbonate replacement features—deposit types that are key global sources of both industrial and precious metals.

Leadership Team

Nikolas Perrault, CFA, Executive Chairman, brings over 35 years of experience in capital markets, securities trading, and strategic advisory roles. He began his career with Canada’s top financial institutions and has since focused on guiding small to mid-cap companies through public listings, M&A, and capital raising. He holds a Chartered Financial Analyst designation and a Bachelor of Commerce.

Luís Martins, President and CEO, brings over 40 years of experience in the exploration and mining sector. He previously served as Director of the Mineral Resources Department at Portugal’s Geological Survey and as Director of Mines and Quarries at the Directorate-General of Energy and Geology. He has coordinated international working groups focused on raw materials and mineral policy and has authored more than 100 scientific publications.

Dr. Sergei Diakov, Chair of the Technical Committee and Senior Advisor, is a globally recognized geologist and former discovery lead at both BHP and AngloGold Ashanti. His track record includes major copper-gold discoveries such as Oyu Tolgoi in Mongolia and Nuevo Chaquiro in Colombia. Dr. Diakov brings decades of senior experience managing exploration teams, overseeing risk across geologic and ESG domains, and executing discovery-driven development strategies.

Adam Cavise, Independent Director, brings over 25 years of capital markets experience and has been directly involved in structuring and closing more than $100 billion in public and private equity offerings, SPACs, and recapitalization transactions. Currently a partner at Revere Securities in New York, he has held senior equity roles at Kingswood, Spartan Capital, and Macquarie, and is well regarded for his deep Wall Street network and leadership in equity capital markets.

Fairchild Gold benefits from a deeply experienced leadership and advisory team with expertise across exploration, capital markets, and corporate development. To view the full team, click here.

Fairchild Gold Corp. (OTC: FCHDF), closed Monday's trading session at $0.0685, off by 5.2559%, on 624,873 volume. The average volume for the last 3 months is 568,410 and the stock's 52-week low/high is $0.0306/$1.

Recent News

• Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF) - MiningNewsBreaks - Fairchild Gold (TSX-V: FAIR) (OTCQB: FCHDF) (Frankfurt: Y4Y) Expands Nevada Titan Property and Initiates CSAMT Survey
• RockBreaks - Fairchild Gold (TSX-V: FAIR; OTCQB: FCHDF; Frankfurt: Y4Y) Receives Updated NI 43-101 Technical Report for Golden Arrow Project
• InvestorNewsBreaks - Fairchild Gold Corp. (TSX.V: FAIR) (OTCQB: FCHDF) Advancing North American Gold and Copper Strategy

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)

Disseminated on behalf of Nevada Organic Phosphate Inc., may include paid advertisements.

The QualityStocks Daily Newsletter would like to spotlight LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT).

• There are several types of technologies for treating tumors with proton therapy, such as pencil beam scanning, passive scattering, and others
• Linac for Image Guided Hadron Therapy, LiGHT system, is believed to offer a more affordable, compact, and efficient design, along with better treatment precision than traditional technologies
• The system complements LIXTE’s lead clinical candidate, LB-100, which is a small-molecule PP2A inhibitor which is designed to enhance the activity of immunotherapy and chemotherapy

Treating tumors with proton therapy is a highly advanced form of radiation that offers high precision, which minimizes radiation exposure for the tissue around the tumor. There are various types of technologies used for treating tumors with proton therapy, such as pencil beam scanning, passive scattering, and others. Pencil beam scanning is when a narrow beam is used to essentially “paint” the tumor with radiation, layer by layer. On the other hand, passive scattering, which is an older technique, is when a narrow proton beam passes through scattering material to create a wider beam to match the size of the tumor. However, Liora Technologies, a subsidiary of LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is bringing something new to the table when it comes to proton therapy with the Linac for Image Guided Hadron Therapy (“LiGHT”) System.

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is a clinical-stage pharmaceutical company developing differentiated cancer therapies built around a novel biological target. Rather than introducing standalone treatments, the company is focused on advancing a first-in-class approach designed to enhance the effectiveness of established cancer therapies, addressing persistent challenges that continue to limit outcomes in oncology.

LIXTE’s work centers on improving how chemotherapy and immunotherapy perform in difficult-to-treat cancers with significant unmet medical need. By translating a distinct scientific concept into therapies that can be integrated into existing treatment frameworks, the company aims to expand the reach and impact of current standards of care without requiring wholesale changes to clinical practice.

Alongside internal development, LIXTE has pursued selective strategic actions that extend its capabilities beyond drug development, supporting its evolution into a platform-oriented oncology company spanning both pharmaceutical and technology-driven approaches.

The company is headquartered in Boca Raton, Florida.

Portfolio

LB-100 (PP2A Inhibitor Platform)

LIXTE’s lead clinical candidate, LB-100, is a proprietary small-molecule inhibitor of protein phosphatase 2A (PP2A) designed to enhance the activity of chemotherapy and immunotherapy. The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by more than 25 published preclinical and translational studies. LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with limited treatment options.

Ongoing trials include combinations of LB-100 with immunotherapy in ovarian clear cell carcinoma and metastatic MSI-low colon cancer, as well as combination therapy with chemotherapy in advanced soft tissue sarcoma. These studies are being conducted in collaboration with leading academic cancer centers and industry partners, reflecting LIXTE’s emphasis on externally validated clinical execution.

Radiotherapy Platform Expansion (Liora Technologies)

In November 2025, LIXTE expanded beyond pharmaceuticals with the acquisition of Liora Technologies Europe Ltd., adding an electronically controlled proton therapy platform known as the LiGHT System. This acquisition established LIXTE’s entry into radiotherapy, complementing its drug development activities and creating optionality for future recurring revenue models tied to jointly operated treatment centers.

Market Opportunity

LIXTE is targeting cancers where existing therapies show limited durability due to resistance, toxicity constraints, or suboptimal patient response. Chemotherapy and immunotherapy are widely applicable across tumor types but remain constrained by these factors, creating an opportunity for approaches that improve efficacy without proportionally increasing toxicity.

The company’s clinical programs focus on ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma, indications characterized by high unmet need and limited effective treatment options. Rather than reshaping oncology care, LIXTE is developing LB-100 to augment existing therapies, an approach that could support wider clinical use within established treatment pathways.

Leadership Team

Geordan Pursglove, Chairman, President and Chief Executive Officer, is an accomplished executive and entrepreneur with more than a decade of experience spanning mergers and acquisitions, capital markets, strategic growth initiatives, and operational leadership across both public and private companies. His background includes leadership roles across technology, logistics, customer experience, sports, and marketing, with a focus on scaling organizations, raising capital, and executing transformative strategies.

Bas van der Baan, Chief Scientific Officer, has more than 20 years of experience in biotechnology with a concentration in oncology and diagnostics. He previously served as Chief Clinical and Business Development Officer at Agendia, where he played a key role in initiating and executing clinical trials that supported the commercialization of precision molecular oncology diagnostics in both the U.S. and Europe.

Peter Stazzone, Chief Financial Officer, brings over two decades of financial management experience across publicly traded and privately held companies. His background includes leading capital raises, mergers and acquisitions, financial controls, and public company reporting, with prior CFO roles at companies including Beyond Commerce, Strainz, and Voice Telecom.

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), closed Monday's trading session at $2.93, up 1.3841%, on 17,817 volume. The average volume for the last 3 months is 76,950 and the stock's 52-week low/high is $0.64/$6.26.

Recent News

• LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) - Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy
• LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands into Proton Therapy Through Liora Technologies, Advancing the LiGHT System for Next-Generation Cancer Care
• BioMedNewsBreaks - LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary

MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF)

The QualityStocks Daily Newsletter would like to spotlight MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF).

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising.

MAX Power Mining (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) has commenced drilling of a second Natural Hydrogen well, “Bracken,” approximately 325 km southwest of the Lawson Discovery near Central Butte, Saskatchewan. The well will test basin-scale continuity under a distinct stratigraphic trapping mechanism at the Grasslands Project, part of the Company’s 1.3 million permitted acres. Bracken targets the interpreted pinch-out of a large reservoir based on 34.3 line kilometres of newly acquired proprietary 2-D seismic data combined with legacy seismic. The location also sits within a known helium fairway and an area where the Company previously identified a rare basement rock assemblage associated with Western Canada’s first known deep subsurface Natural Hydrogen occurrence. The program also supports further refinement of MAX Power’s in-house and AI-assisted MAXX LEMI (Large Earth Model Integration) model for predictive Natural Hydrogen targeting.

To view the full press release, visit https://ibn.fm/90x2P

MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) is a Canadian mineral exploration company pioneering the development of natural hydrogen as a potential new primary energy source. As a first mover in this emerging sector, the company has assembled North America’s largest permitted land package targeting naturally occurring, emissions-free hydrogen accumulations in the earth’s subsurface.

MAX Power plans to commence Canada’s first dedicated deep drilling program for natural hydrogen in November 2025, starting on the 200-km-long Genesis Trend in southern Saskatchewan, with the goal of converting a discovery into the world’s first commercial natural hydrogen venture in 2026.

Backed by institutional partnerships and a highly experienced technical team, MAX Power continues to build a globally recognized brand in the natural hydrogen sector. Its massive land package in Saskatchewan currently comprises 1.3 million permitted acres with another 5.7 million acres under application.

Saskatchewan, a jurisdiction recognized for its supportive regulatory environment and clean energy innovation, features North America’s most advanced policy framework for the exploration and development of natural hydrogen. The province is also known for its spectacular resource endowment as the world’s leading potash provider, the top high-grade uranium producer in the world, and Canada’s second-largest oil producer. Saskatchewan is also Canada’s leader in helium production, geothermal energy and carbon capture.

The company’s head offices are in Saskatchewan’s two largest cities, Saskatoon and Regina.

Projects

Natural Hydrogen (Saskatchewan)

MAX Power holds multiple large land packages across Saskatchewan prospective for deposits of natural hydrogen, highlighted by the 200-km-long Genesis Trend and the 75-km-wide Grasslands Project.

Genesis features easy road, rail and power access and a proposed hydrogen hub on its eastern side where there is an abundance of potential end-users for natural hydrogen. Drilling is set to begin in early November 2025 at the Lawson target situated in the heart of Genesis. Canada’s first deep well for natural hydrogen is specifically designed to test a complete five-element hydrogen system interpreted to exist at Lawson: source rocks, migration pathways, reservoirs, seals, and traps. Data from vintage and proprietary 2D seismic, gravity and magnetic surveys, and subsurface mapping, among other geological and geophysical information, support the prospectivity of Lawson which lies adjacent to an extensive regional “Salt Barrier” offering excellent seal and trap conditions.

The Genesis Trend’s scalability is further demonstrated by the recent identification of the Lucky Lake target, approximately 50 km northwest of Lawson and one of at least 20 Lawson “look-a-likes” that is being investigated along the trend. Early interpretation suggests serpentinized rocks and structural features favorable for hydrogen generation exist at Lucky Lake.

At Grasslands, geologists are excited about a broad area in the vicinity of a well (“Climax”) near the U.S. border that was drilled a few years ago and inadvertently resulted in Canada’s first known deep subsurface occurrence of natural hydrogen, associated with a rare rock assemblage geologists refer to as “exotic terrane”. Permits covering an area stretching 75 km east-west and up to 10 km north-south were acquired by MAX Power next to this discovery, amplifying the company’s first-mover advantage. Adjacent to three sides of Grasslands are producing helium wells owned by privately-held North American Helium, demonstrating that this under-explored area of the province is highly prospective for clean gas. Drilling of a target at Grasslands is expected during Q1 2026.

Other MAX Power land packages are Rider 1, 2 and 3 in the southeast part of the province, and Choiceland in the north-central part of the province.

To enhance scientific rigor and accelerate development, MAX Power has established a multi-year strategic collaboration with the Petroleum Technology Research Centre (PTRC), a globally recognized leader in subsurface energy research based in Regina, Saskatchewan. This partnership complements the company’s relocation to Innovation Saskatchewan’s R+T Parks in Saskatoon and Regina, placing its technical and executive teams at the heart of the province’s academic, regulatory, and infrastructure ecosystem.

Critical Minerals

MAX Power’s other key asset is its Wilcox Lithium Project in mining-friendly Cochise County in southeast Arizona where first-ever diamond drilling in late 2023/early 2024 confirmed the discovery of near-surface lithium-rich clays over a broad area of the Willcox Playa. MAX Power’s property occurs within a nearly 4,000-acre corridor adjacent to U.S. Department of Defense land, and benefits from direct access through roads, rail and power infrastructure. The discovery was made just as lithium entered its final price downturn and is now being intensely revisited by the company in light of the turnaround in lithium and an emphasis on critical mineral resource development in the United States under the Trump administration.

Market Opportunity

According to company materials, the global hydrogen market is valued at approximately $250 billion and is expected to surpass $400 billion by 2030. Supporting this outlook, a study published in Science Advances (Dec. 2024) estimates that in-place natural hydrogen resources could meet global net-zero carbon goals for roughly 200 years. Closer to home, a feasibility study by the Transition Accelerator (April 2024) projects that the Regina-Moose Jaw Industrial Corridor (RMJIC) in Saskatchewan could support a C$708 million annual hydrogen market, with province-wide demand reaching as high as C$2.7 billion per year.

These projections underscore a compelling opportunity to establish a new energy economy centered around natural hydrogen—a low-cost, low-emission, and potentially naturally replenishing resource. MAX Power is well-positioned to lead this effort with proximity to infrastructure, favorable geology, and increasing institutional support.

Leadership Team

Mansoor Jan, CEO, brings more than two decades of international experience across mining operations, capital markets, and business development. He has held senior positions at BHP Australia, BHP Chile, and Rio Tinto, where he was responsible for advancing cross-border projects, driving mine optimization, and leading technology delivery across major jurisdictions. Mr. Jan holds a BA and MSc in Economics and a Master of Commerce from the University of New South Wales in Australia.

Neil McMillan, Director and Chair of the Audit Committee, is the former Chairman of the Board of Cameco, the world’s largest publicly traded uranium company. Mr. McMillan served on Cameco’s board for 16 years and is highly regarded within and outside the province for his decades of success there. He previously led Claude Resources as President and CEO, paving the way for its development into Saskatchewan’s only profitable gold miner which was bought out for more than $300 million by Silver Standard Resources in 2014.

Steve Halabura, Chief Geoscientist, has decades of successful experience in the province’s resource sector including a deep understanding of the geological controls on the accumulation of hydrogen, helium, and other industrial gases. He was also instrumental in the early formative stages of the only two Saskatchewan greenfield potash mines to come into existence in the 21st century, these being BHP’s Jansen Project and K+S’s Bethune mine. Jansen is the largest private investment ($14 billion) in Saskatchewan history and is located northeast of MAX Power’s Genesis Trend.

Tom Kishchuk, MAX Power’s Senior Strategic Advisor for Natural Hydrogen Development, is CEO for the Saskatchewan-based Global Institute for Energy, Mines and Society (GIEMS). He has over three decades of technical and business leadership in national and global organizations focused on the energy sector.

MAX Power Mining Corp. (OTC: MAXXF), closed Monday's trading session at $1.0735, off by 7.4569%, on 138,456 volume. The average volume for the last 3 months is 807,480 and the stock's 52-week low/high is $0.105/$1.3.

Recent News

• MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) - AINewsBreaks - MAX Power Mining (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) Commences Second Natural Hydrogen Well At Grasslands Project
• MiningNewsBreaks - MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) Hits Natural Hydrogen in Landmark Saskatchewan Drill Program
• MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) Natural Hydrogen Vision Gains Momentum with Major $5M Investment

NRx Pharmaceuticals Inc. (NASDAQ: NRXP)

The QualityStocks Daily Newsletter would like to spotlight NRx Pharmaceuticals Inc. (NASDAQ: NRXP).

NRx Pharmaceuticals (NASDAQ: NRXP) , a clinical-stage biopharmaceutical company, has appointed Prof. Joshua C. Brown, MD, PhD, as Chief Medical Innovation Officer. Prof. Brown is a psychiatrist, neurologist and neuroscientist who studies the mechanisms of Transcranial Magnetic Stimulation (TMS) and their translation into clinical optimization. He serves as Medical Director of the McLean Hospital TMS Service, Director of TMS research and founding director of the Brain Stimulation Mechanisms Laboratory, with more than $20 million in federal funding from the National Institute of Mental Health and the Defense Advanced Research Projects Agency. At NRx, he will support development of mechanistically informed neuropsychiatric therapeutics, including NRX-101 (D-cycloserine/lurasidone), and collaborate on advancing treatments for depression and PTSD across the company’s HOPE Therapeutics clinic network.

To view the full press release, visit https://ibn.fm/8VtM4

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with a particular emphasis on conditions characterized by acute suicidality. The company is leveraging its proprietary NMDA receptor modulation platform to address significant unmet medical needs in suicidal depression, bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD).

With a commitment to advancing life-saving treatments, NRx is developing novel therapeutics aimed at providing safer and more effective alternatives to current treatment options. Its lead investigational drug, NRX-101, is positioned to be the first FDA-approved oral therapy for suicidal bipolar depression. Additionally, the company is working to bring NRX-100 (intravenous ketamine) to market as an approved treatment for acute suicidal depression, a condition for which existing treatments remain limited.

By integrating cutting-edge science with a patient-focused mission, NRx aims to transform the standard of care for individuals suffering from severe psychiatric and neurological conditions.

NRx has also established HOPE Therapeutics, a subsidiary focused on delivering interventional psychiatric care through a nationwide clinic network. HOPE Therapeutics aims to become the first coordinated system of care for suicidal depression and PTSD, combining ketamine, Transcranial Magnetic Stimulation (TMS), digital therapeutics, and other precision psychiatry tools in a supervised clinical environment.

NRx is headquartered in Wilmington, Delaware. HOPE is headquartered in Miami, Florida.

Product Portfolio

NRx Pharmaceuticals’ pipeline includes multiple late-stage therapeutic candidates targeting psychiatric and neurological disorders:

• NRX-100: A preservative free intravenous ketamine formulation under development for acute suicidal depression, backed by strong clinical trial data and Fast Track designation from the FDA.
• NRX-101: An oral therapy with a dual mechanism targeting NMDA and 5-HT2A receptors, designed for patients with suicidal treatment-resistant bipolar depression. The drug has received Breakthrough Therapy designation from the FDA.
• Expanded Research: The company is further evaluating NRX-101 as a potential non-opioid treatment for chronic pain and a therapy for complicated urinary tract infections.

NRx’s therapeutic pipeline is designed to address conditions with limited or no treatment options, with the potential to improve patient outcomes and expand the standard of care.

HOPE Therapeutics

HOPE Therapeutics, a wholly owned subsidiary of NRx Pharmaceuticals, is establishing a national network of psychiatrist-led clinics focused on suicidal depression and PTSD. Its care model integrates preservative-free ketamine, TMS, digital therapeutics, and supervised psychiatric support to deliver rapid, measurable outcomes.

The company is targeting more than 30 clinic acquisitions by year-end 2025. Recent agreements include the acquisition of Dura Medical and a letter of intent with Neurospa TMS, strengthening HOPE’s foundation in interventional psychiatry. In April, HOPE also secured a term sheet for strategic investment from a global medical device manufacturer.

With ketamine sales already underway under a 503B license, HOPE projects $100 million in annual revenue and profitability by year-end 2025. Positioned as a standalone care delivery company, HOPE offers NRx a potential future spinout opportunity to unlock additional shareholder value.

Market Opportunity

The need for innovative treatments in mental health and pain management is substantial. Suicide is a leading cause of death in the United States, claiming nearly 50,000 lives each year, with over 12 million adults seriously considering suicide annually, according to the CDC.

Suicidal depression, a distinct and life-threatening condition, affects approximately 3.5 million Americans. Despite this prevalence, the only approved intervention remains electroconvulsive therapy (ECT), a treatment with significant side effects and limited access. NRx aims to address this urgent gap with NRX-100, a preservative-free intravenous ketamine formulation being developed as the first FDA-approved treatment specifically for suicidal depression.

Additionally, approximately 7 million Americans suffer from bipolar depression, a condition where nearly half of patients will attempt suicide during their lifetime and one in five may die by suicide. NRX-101, NRx’s oral drug candidate, targets this critical unmet need as a potential first-in-class therapy specifically for bipolar depression.

Beyond mood disorders, chronic pain affects over 50 million individuals in the U.S., and PTSD impacts more than 12 million people—conditions for which few non-opioid, fast-acting treatments are available. By addressing these high-risk, underserved populations, NRx Pharmaceuticals is positioned to enter multiple billion-dollar markets and reshape the standard of care for severe psychiatric and neurological illnesses.

Leadership Team

Jonathan C. Javitt, Founder, Chairman & Chief Executive Officer or NRx, and Co-CEO of HOPE, brings four decades of experience in pharmaceutical and medical device development. He has led blockbuster drug and device programs at major companies, including Allergan, Merck, and Novartis, and has served as an advisor to four U.S. presidential administrations.

Michael Abrams, Chief Financial Officer, has nearly 30 years of experience in finance, having served in executive roles, including CFO positions at Arch Therapeutics and FitLife Brands. His expertise spans investment banking, corporate finance, and business strategy.

Rick Panicucci, Chief Technology Officer, has more than 25 years of leadership in pharmaceutical manufacturing and process development. He has held key positions at Novartis, WuXi AppTec, and other major companies, leading multiple approved New Drug Applications.

Matthew Duffy, Chief Business Officer, NRx, Co-CEO of HOPE, has over 35 years of experience in biotechnology business development and investment banking. He has held leadership roles at Pfizer, MedImmune, and several financial institutions, specializing in corporate strategy and partnerships.

NRx Pharmaceuticals Inc. (NASDAQ: NRXP), closed Monday's trading session at $1.805, off by 2.957%, on 366,564 volume. The average volume for the last 3 months is 566,308 and the stock's 52-week low/high is $1.58/$3.84.

Recent News

• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) - PsychedelicNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer
• BioMedNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway
• PsychedelicNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Licenses Real-World Evidence From 70,000 Patients to Support FDA Accelerated Approval of NRX-100

Nightfood Holdings Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (OTCQB: NGTF).

• TechForce Robotics announced that the company has secured full ownership of the Intellectual Property for BIM-E, an autonomous beverage robotics platform
• This announcement follows the successful debut of the platform at CES 2026 in Las Vegas, where the company reported strong industry engagement, reinforcing confidence in the commercial viability of the platform
• Following CES, NGTF has initiated steps to ramp up manufacturing readiness, expand development teams, and more

Nightfood Holdings Inc. (d.b.a. TechForce Robotics) (OTCQB: NGTF) , an emerging robotics company focused on deploying AI-Enhanced automation across multiple industries, recently announced that it has completed a comprehensive intellectual property acquisition of the BIM-E Autonomous Beverage Robotics Platform ( ibn.fm/uesFt ).

Nightfood Holdings Inc. (OTCQB: NGTF) is a hospitality technology and asset acquisition company revolutionizing hotel operations through AI-driven service robotics and strategic property acquisitions. By integrating advanced automation solutions with high-value hospitality assets, NGTF is setting a new standard for operational efficiency, cost reduction, and labor optimization in the hospitality industry.

With a focus on Robotics-as-a-Service (RaaS) and hotel ownership, NGTF is uniquely positioned at the intersection of technology and real estate, creating scalable, revenue-generating solutions that drive the widespread adoption of automation in the hospitality sector.

Operations

Nightfood Holdings is focused on two core business areas:

• Hotel Acquisitions & Operations – NGTF is acquiring a portfolio of independent hospitality properties, spanning various market segments from midscale to luxury. These hotels serve as real-world testbeds for automation technologies, allowing NGTF to refine its RaaS solutions before deploying them at scale.
• Robotics-as-a-Service (RaaS) for Hospitality – NGTF provides subscription-based, AI-driven robotic automation, designed to optimize hotel operations. By deploying standardized automation solutions, NGTF helps hotels reduce costs, improve labor efficiency, and enhance guest experiences.

Through this fully integrated model, NGTF ensures that its robotics solutions are tested, optimized, and proven profitable before expanding to third-party hotel operators.

Market Opportunity

The demand for automation in hospitality is accelerating, driven by labor shortages, rising costs, and increased competition. NGTF is positioned to capitalize on this shift through its combined hotel ownership and RaaS strategy.

• Total Addressable Market (TAM): The global service robotics market is projected to reach approximately $107.75 billion by 2030, driven by widespread adoption across industries including hospitality, according to Research and Markets.
• Serviceable Available Market (SAM): The global smart hospitality market, which includes AI and automation technologies for hotels, is projected to reach $186.10 billion by 2032, according to SNS Insider.
• Competitive Positioning: NGTF’s unique real estate + automation model allows it to implement cost-saving robotics solutions in real-world environments before expanding adoption across the industry.

Industry Impact: The Future of Smart Hotels

NGTF is at the forefront of next-generation hospitality automation, transforming how hotels operate. By combining AI-powered service robotics with real estate acquisitions, NGTF is pioneering the transition to smart, highly efficient hotel environments.

Hotels acquired by NGTF serve as testing grounds for robotics deployment, allowing the company to continuously refine its automation solutions. The biggest industry benefits include:

• Cost Savings for Hotel Operators – Reducing labor costs and improving operational efficiency.
• Scalability & Standardization – Offering a streamlined, subscription-based RaaS model for seamless automation adoption.
• Industry Leadership in Hotel Robotics – Driving the transformation of hospitality with AI-powered automation solutions.

Future Vision & Growth Strategy

Over the next three to five years, NGTF is committed to scaling both its hotel portfolio and RaaS adoption. By refining and optimizing its automation technologies in its own properties, NGTF will continue deploying RaaS to third-party hotel operators, positioning itself as a leader in next-generation hospitality automation.

Through strategic acquisitions and AI-driven solutions, NGTF is defining the future of smart hotels—delivering cost-efficient, scalable automation that reshapes the hospitality landscape.

Team Expertise as a Strategic Advantage

In addition to technology and real estate, NGTF’s most powerful asset is its team. The company’s leadership and operating partners bring deep expertise in both hospitality and food service, having collectively developed over 50 properties, managed more than 130 hotels, and supported more than 6,000 quick-service restaurants.

This wealth of experience enables NGTF to execute its automation and acquisition strategy with operational discipline, industry insight, and scale—further strengthening its position in next-generation hospitality.

Nightfood Holdings Inc. (OTCQB: NGTF), closed Monday's trading session at $0.043287, off by 1.1712%, on 654,401 volume. The average volume for the last 3 months is 1,129,530 and the stock's 52-week low/high is $0.0061/$0.114.

Recent News

• Nightfood Holdings Inc. (OTCQB: NGTF) - TechForce Robotics (NGTF) Secures Full Ownership of BIM-E IP, Bolstering Robotics Ecosystem Amidst an Industry Transition
• TechMediaBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Featured in NetworkNewsAudio on AI Service Robotics Commercialization
• AINewsBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Featured in AINewsWire Editorial on AI-Driven Service Robotics

Renewal Fuels Inc. (OTC: RNWF)

The QualityStocks Daily Newsletter would like to spotlight Renewal Fuels Inc. (OTC: RNWF).

• Renewal Fuels is repositioning itself as an infrastructure-focused fusion energy company following its merger with Kepler Fusion Technologies, building a public-company framework aimed at long-term deployment of modular fusion systems for industrial power markets.
• The company has added senior technical and legal leadership to support its fusion commercialization strategy, with veteran plasma physicist Dr. John E. Brandenburg being appointed Chief Technology Officer, and intellectual property specialist Michael G. Smith appointed Chief Legal Officer and board director.
• The company has also filed three new federal trademark applications, expanding protection around the Texatron(TM) platform and American Fusion brand.

Renewal Fuels (OTC: RNWF) (d/b/a American Fusion), an advanced energy platform company focused on the development and commercialization of fusion energy technologies, has announced technical and corporate foundations, with key executive appointments and new trademark filings.

Renewal Fuels (OTC: RNWF) announced that all closing conditions related to its previously disclosed transaction with Kepler Fusion Technologies Inc. have been satisfied, formally closing the transaction effective Feb. 27, 2026, for accounting purposes. The definitive closing date supports purchase price accounting clarity and simplifies the Company’s fiscal 2025 year-end audit, which is nearing completion. Management said the completion enables finalization of acquisition accounting and related disclosures as the Company progresses toward full SEC reporting status. Separately, Renewal Fuels refiled its Motion for Entry of Default Judgment in a pending Washington matter with additional specificity requested by the court. The Company also continues advancing patent filings tied to its Texatron(TM) platform, preparing its substantially complete Form 10 registration statement under the Securities Exchange Act of 1934, securing EDGAR access codes for near-term filing, progressing a nearly complete PCAOB audit for fiscal years 2024 and 2025, and pursuing a FINRA corporate action related to its transition to American Fusion, including preferred trading symbols AFTX, AMFN or AFEI, subject to regulatory review.

To view the full press release, visit: https://ibn.fm/3LRuq

Renewal Fuels Inc. (OTC: RNWF) (d/b/a American Fusion) is an advanced energy platform company focused on building a scalable, infrastructure-grade fusion energy business through its wholly owned subsidiary, Kepler Fusion Technologies. Following a completed reverse merger with Kepler, the company has repositioned itself around the development and long-term commercialization of deployable fusion power systems designed for real-world industrial and infrastructure use rather than experimental research programs.

The company’s strategy centers on pairing proprietary fusion technology with disciplined governance, intellectual property development, and a public-company operating framework intended to support long-duration value creation. Management has emphasized transparency, regulatory readiness, and institutional credibility as foundational elements alongside continued technical progress.

Renewal Fuels is in the process of transitioning its public identity to American Fusion to reflect its strategic focus on advanced fusion energy infrastructure and commercialization.

The company is based in Southlake, Texas.

Kepler Texatron™

Through wholly owned subsidiary, Kepler Fusion Technologies, the company is developing the Texatron™ aneutronic fusion platform, a compact, pulsed fusion system engineered specifically for commercial and infrastructure-grade deployment. Unlike steady-state fusion concepts that prioritize laboratory demonstration, the Texatron™ operates in controlled cycles designed to support modular scalability, redundancy, and distributed installation across multiple end markets.

The platform is optimized around a Deuterium–Helium-3 fuel pathway that enables direct electrical energy conversion, reducing reliance on traditional steam cycles and minimizing neutron-related material degradation. This design supports a smaller physical footprint and greater flexibility for deployment in grid-constrained or mission-critical environments such as data centers, industrial facilities, defense installations, and remote locations.

Kepler’s commercialization model is structured around a Power-as-a-Service approach under which the company intends to retain ownership of its fusion units and sell electricity to customers under long-term contractual arrangements. This infrastructure-oriented model is designed to align system deployment with predictable, recurring revenue while allowing for fleet-based scaling over time. The platform is supported by a broad and expanding intellectual property estate encompassing reactor architecture, energy conversion systems, control technologies, manufacturing processes, and deployment methodologies.

Market Opportunity

U.S. electricity demand has re-entered a period of sustained growth following nearly two decades of relative stagnation, according to data from the U.S. Energy Information Administration. After years in which efficiency gains and structural economic shifts largely offset population and economic growth, electricity consumption has increased meaningfully since 2020 and is forecast to continue rising through at least the middle of the decade.

Recent and projected growth is being driven primarily by the commercial and industrial sectors, with data centers, advanced manufacturing, and other power-intensive operations accounting for a disproportionate share of incremental demand. These segments tend to require continuous, non-intermittent electricity supply, placing increased pressure on existing generation and transmission infrastructure.

This shift underscores a growing need for reliable baseload power sources that can be deployed without extensive new transmission build-out and that align with emissions-reduction objectives. Fusion-based energy systems designed for distributed, infrastructure-grade deployment represent a potential long-term solution for meeting rising demand in environments where reliability, resilience, and scalability are critical.

Leadership Team

Richard Hawkins, Chairman and Chief Executive Officer, has overseen the company’s strategic reset, corporate restructuring, and transition toward an advanced fusion energy platform, with responsibility for governance, capital markets strategy, and long-term corporate development.

Brent Nelson, Chief Executive Officer of Kepler Fusion Technologies, brings extensive experience in energy systems and commercialization strategy and leads the development, validation, and deployment roadmap for the Texatron™ fusion platform, as well as Kepler’s intellectual property and operating model.

Renewal Fuels Inc. (OTC: RNWF), closed Monday's trading session at $0.0396, up 11.236%, on 20,488,028 volume. The average volume for the last 3 months is 16,411,620 and the stock's 52-week low/high is $0.000001/$0.045.

Recent News

• Renewal Fuels Inc. (OTC: RNWF) - GreenEnergyBreaks - Renewal Fuels, Inc. (OTC: RNWF) Closes Kepler Fusion Transaction, Advances SEC Reporting and American Fusion Transition
• Renewal Fuels Inc. (RNWF) Strengthens Leadership Bench and IP Strategy as It Drives New Approach Toward Commercial Fusion Energy
• GreenEnergyBreaks - Renewal Fuels, Inc. (OTC: RNWF) Provides Court Update on Share Rescission Case

Safe Pro Group Inc. (NASDAQ: SPAI)

The QualityStocks Daily Newsletter would like to spotlight Safe Pro Group Inc. (NASDAQ: SPAI).

Safe Pro Group (NASDAQ: SPAI) , a developer of AI-enabled defense, security and situational awareness solutions, announced it completed full delivery of its $1,000,000 AI-powered edge processing systems to the U.S. Government within 15 days of receiving the award. The Company said the rapid execution marks an operational milestone as it advances commercialization of its patented AI product portfolio and strengthens its past performance record under U.S. Government programs. Management noted the achievement reinforces confidence in Safe Pro’s ability to deliver under government contracts, while the Company continues pursuing additional opportunities with U.S. agencies, prime contractors and allied international partners.

To view the full press release, visit https://ibn.fm/Tiu80

Safe Pro Group Inc. (NASDAQ: SPAI) is a mission-driven technology company delivering advanced AI-powered security and defense solutions. It is focused on serving customers in the defense, homeland security, humanitarian, law enforcement, and commercial markets where its AI, drone-based services and ballistic protective gear can synergistically deliver safety and operational efficiency.

At the heart of Safe Pro’s mission is its patented artificial intelligence (AI), machine learning (ML), deep learning and applied computer vision software technology. These tools are currently being used to rapidly detect small objects in drone-based video and imagery such as landmines and unexploded ordnance (UXO), enabling safer and more efficient field operations across global conflict and post-conflict zones and supporting efforts to improve the reliability of critical infrastructure. The company’s vision is to lead the evolution of security and threat detection through AI innovation, while its mission is to empower governments, enterprises, and humanitarian organizations with tools to respond to evolving threats at scale.

With a team of leaders and subject matter experts drawn from the defense, technology, and public safety sectors, Safe Pro Group delivers U.S.-developed next-generation AI and drone services through its Safe Pro AI and Airborne Response units and high-performance, American-made ballistic protective solutions through its Safe-Pro USA subsidiary.

The company is headquartered in Aventura, Florida.

Products

Safe Pro Group’s three business units operate across software, hardware, and field services to deliver a comprehensive suite of solutions. Each division plays a distinct role in supporting defense, humanitarian and public safety missions around the world.

Safe Pro AI

Safe Pro AI’s core AI-powered computer vision technology enables the rapid analysis of drone-based imagery to autonomously detect objects of interest. Its flagship product, SpotlightAI™ can detect and label over 150 types of explosive threats including landmines, cluster munitions, and unexploded ordnance (UXO). Built on more than two years of real-world usage in Ukraine and now including additional imagery being gathered from the Asian-Pacific region and Africa, SpotlightAI™ rapidly processes and creates high-resolution maps supported by the hyper scalability of the Amazon Web Services (AWS) cloud or detects threats in real-time locally through its OnSite Windows-based software application. Today, the platform boasts one of the world’s largest datasets built on over 1.6 million real-world battlefield images from Ukraine, identifying 28,000+ threats across more than 6,750 hectares, an area equivalent in size to Manhattan.

Airborne Response

Airborne Response is a leading provider of mission critical drone services using U.S. Government-compliant small uncrewed aircraft systems (sUAS) (drones). It serves enterprises in utilities & telecom and insurance with a full-range of drone-based critical infrastructure inspection and monitoring solutions as well as Drone-as-a-First Responder (DFR) services for law enforcement and public safety. It provides customers with actionable intelligence though data capture, analytics and processing powered by AI.

Safe-Pro USA

Safe-Pro USA manufactures ultra-premium, American-made ballistic protection systems including advanced body armor and ballistic plates as well as complete Explosive Ordnance Disposal (EOD) suits, demining aprons, and bomb blankets. All products exceed U.S. and NATO standards and are designed, engineered, and produced in the U.S., supporting customers across military, humanitarian, and law enforcement sectors.

Market Opportunity

Harnessing its patented, real-time, AI-powered processing of drone-based imagery, Safe Pro is creating a uniquely powerful ‘Next-Gen’ approach to situational awareness supporting ground-based personnel in safely completing their defense/military, humanitarian, law enforcement & commercial missions.

The global threat posed by landmines and UXO spans nearly 60 countries, affecting millions of civilians and imposing significant economic burdens, particularly in agriculture and infrastructure. In Ukraine alone, the contamination of 17 million hectares has resulted in $50+ billion in agricultural losses, with World Bank estimates projecting $30 billion needed in demining costs. According to the Landmine Monitor 2024, regions in Asia, Africa, and Latin America continue to report high casualty rates.

Safe Pro is positioned to capture a portion of the $15 billion+ global defense tech market, especially in AI-driven battlefield intelligence, drone surveillance, and threat detection. As a U.S.-based AI and defense technology provider with a HUBZone-certified manufacturing arm, Safe Pro is eligible for federal and state procurement programs, public safety grants, and critical infrastructure contracts, as well as global humanitarian demining efforts.

Leadership Team

Dan Erdberg, Chairman and CEO, brings over 20 years of experience as a C-level technology executive. He has led multiple Nasdaq listings in the drone, 5G, and satellite communications sectors, raised over $50 million in growth capital, and spearheaded Safe Pro Group’s corporate strategy and acquisitions.

Theresa Carlise, Chief Financial Officer, has more than 30 years of experience in financial leadership roles for public companies. Her expertise includes equity transactions, strategic planning, and financial restructuring. She served as Chief Financial Officer, Secretary, Treasurer and Director of various publicly traded companies within the retail, telecommunications, distribution, transportation, mortgage banking and construction sectors.

Pravin Borkar, CTO and Director (President, Safe-Pro USA), has over 30 years of experience in the engineering and manufacturing of ballistic protection systems for the U.S. Department of Defense. He has developed armor solutions for personnel and aircraft platforms including the CH-53 and Blackhawk.

Christopher Todd, President (Airborne Response), is a drone industry veteran and Certified Emergency Manager (CEM®) with more than 30 years of experience. He founded Airborne Response and is President of AUVSI Florida, with expertise in public safety drone deployment and emergency response.

Safe Pro Group Inc. (NASDAQ: SPAI), closed Monday's trading session at $5.51, up 7.8278%, on 708,750 volume. The average volume for the last 3 months is 477,995 and the stock's 52-week low/high is $1.47/$9.1599.

Recent News

• Safe Pro Group Inc. (NASDAQ: SPAI) - DefenseNewsBreaks - Safe Pro Group Inc. (NASDAQ: SPAI) Completes $1M AI Edge System Delivery to U.S. Government in 15 Days
• NetworkNewsBreaks - Safe Pro Group Inc. (NASDAQ: SPAI) Featured in NetworkNewsAudio Release on AI-Enabled Edge Systems
• TechMediaBreaks - SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Upgrades Overwatch With Universal Export for GPS-Denied Drone Navigation

SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF)

The QualityStocks Daily Newsletter would like to spotlight SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF).

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising.

SPARC AI (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) , developer of the Overwatch GPS-denied navigation and targeting platform, has appointed Matt McCrann as Chief Executive Officer of its U.S. subsidiary to lead North American expansion and deepen engagement with U.S. defense, federal and allied government customers. McCrann previously served as CEO of DroneShield’s U.S. subsidiary, where he established and scaled operations during a period of significant revenue growth across federal markets. In his new role, he will focus on building U.S. operational infrastructure, advancing field evaluations and pilot programs, aligning with procurement pathways and forming partnerships with defense primes and system integrators to support adoption of the Overwatch platform across air, land and maritime domains.

To view the full press release, visit https://ibn.fm/VmWWC

SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) develops next-generation, GPS-free target acquisition system and autonomous navigation software for drones and edge devices. Its zero-signature technology delivers real-time detection, tracking, and behavioral insights without reliance on radar, lidar, or heavy sensors. The company’s platform transforms unmanned systems into autonomous tools capable of identifying and engaging targets in GPS-denied environments.

The company’s vision is to redefine situational awareness by merging advanced mathematics, AI modeling, and edge computing into a unified intelligence architecture. SPARC AI aims to empower defense, rescue, and commercial organizations to operate safely and effectively in signal-contested environments where traditional navigation systems fail.

Its mission is to build the world’s most trusted geolocation intelligence platform that operates without GPS, enabling seamless interoperability across air, land, and sea devices.

SPARC AI is headquartered in Toronto, Canada.

Technology

SPARC AI’s technology suite delivers precision target acquisition, navigation, and autonomous intelligence in environments where GPS and traditional sensors fail. At its core is the Target Acquisition System, a software-only solution that determines the geolocation of any visible object using camera telemetry data. By removing the need for specialized hardware like lasers, radar, or lidar, the platform reduces weight, power use, and cost. Built on advanced mathematical modeling, it constructs a 3D understanding of terrain and position, achieving GPS-level accuracy in a zero-signature configuration suited for defense, rescue, and commercial operations.

SPARC AI Mobile extends this capability to handheld and field-issued devices, allowing operators to mark and transmit target coordinates directly from smartphones or rugged tablets. Once a target is identified, the device relays the coordinates to a connected drone, which autonomously navigates to the location for reconnaissance or engagement. The mobile system maintains accuracy even in GPS-jammed or degraded environments, turning each device into a connected node within a broader distributed network.

The company’s GPS-Denied Navigation engine enables mission planning and execution without satellite signals. Operators can design flight paths, define perimeters, and simulate routes to identify optimal vantage points and minimize resource use. Counter-surveillance and threat-prediction tools model adversarial visibility, helping users avoid detection and maximize ground coverage. Together, these capabilities form the foundation of SPARC AI’s software architecture, providing the intelligence backbone for its integrated command platform.

Overwatch Target Intelligence

Overwatch unifies all SPARC AI technologies, including its Target Acquisition, Mobile, and Navigation systems, into a single mission-ready platform that fuses detection, classification, tracking, and navigation in real time. It transforms drones and robotic systems into fully autonomous intelligence assets by synchronizing data across connected devices. The platform’s zero-signature design ensures complete operational security, allowing defense and rescue teams to conduct surveillance, reconnaissance, and engagement without GPS or active sensors.

Within Overwatch, the ATLAS Visibility Intelligence Engine enhances mission planning and reconnaissance through 2D and 3D visualization. Users can simulate line-of-sight coverage from any altitude, identify unseen or occluded areas, and optimize routes for surveillance or search and rescue. Operating entirely through software, ATLAS produces high-fidelity visibility data without mapping drones or additional power consumption, providing a lightweight, silent, and sensor-free alternative to lidar-based systems.

The SPARC AI SDK and open API framework extend Overwatch’s interoperability. Developers can embed SPARC AI’s intelligence into third-party systems such as PX4- and ArduPilot-powered drones, the world’s most widely used open-source flight platforms. The SDK provides REST APIs with bindings for Python, C++, and JavaScript and supports hardware including NVIDIA Jetson, Qualcomm Robotics RB5, and Raspberry Pi. Through these integrations, Overwatch serves as the command and intelligence layer of SPARC AI’s ecosystem, linking distributed drones, sensors, and edge devices into a coordinated autonomous network that operates entirely without GPS.

Market Opportunity

SPARC AI operates within the rapidly expanding defense, security, and commercial drone markets projected to exceed $100 billion over the next decade. The company’s software-defined approach addresses the global demand for autonomous systems capable of performing in denied, degraded, intermittent, and limited (DDIL) environments, positioning SPARC AI at the forefront of next-generation geolocation and targeting solutions.

Fortune Business Insights projects the global commercial drone market will reach approximately $65.25 billion by 2032, while Grand View Research estimates the combined drone hardware and services market will grow to $163.6 billion by 2030. With its per-device subscription model and integration across drones and robotic systems, SPARC AI is structured to capture recurring revenue from this accelerating adoption of GPS-denied intelligence technologies.

Leadership Team

Anoosh Manzoori, CEO, brings extensive experience as a technology entrepreneur, investor, and director, having founded, scaled, and exited multiple high-tech companies. He has taken five companies public, served on seven public company boards, and invested in innovations spanning cloud, fintech, biotech, IoT, defense, and AI.

Justin Hanka, Director, is an investment banking professional with 25 years of experience in mergers and acquisitions and capital markets. He has held executive roles at high-growth companies including iSelect.com.au and Helpmechoose, achieving multiple successful exits.

Anthony Haberfield, Director, is an international financial services executive with 30 years of experience across the Asia Pacific region, specializing in strategy, transformation, procurement, and emerging technology.

SPARC AI Inc. (OTCQB: SPAIF), closed Monday's trading session at $1.232, up 12%, on 129,208 volume. The average volume for the last 3 months is 92,380 and the stock's 52-week low/high is $0.0792/$1.3.

Recent News

• SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) - TechMediaBreaks - SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Appoints Matt McCrann As CEO Of U.S. Subsidiary
• TechMediaBreaks - SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Expands Into Ukraine With GPS-Denied Navigation Partnership
• The Software Fix for Drone Drift: How SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) Is Targeting Reliability at Scale

Wearable Devices Ltd. (NASDAQ: WLDS)

The QualityStocks Daily Newsletter would like to spotlight Wearable Devices Ltd. (NASDAQ: WLDS).

Wearable Devices (NASDAQ: WLDS) , a technology growth company specializing in AI-powered touchless sensing wearables, announced it will debut its Mudra Experience Studio at MWC Barcelona 2026, showcasing a platform designed to create neural input experiences for extended reality and AI applications. Exhibiting at Hall 5 – Booth 5E61 from March 2 to March 5, 2026, the Company will offer live demonstrations of its prompt-based system that transforms neural input into ready-to-deploy gesture experiences, reducing development complexity and accelerating deployment. Wearable Devices will also highlight its Mudra Link neural wristband, a cross-platform gesture-control device compatible with Android, iOS and PC, including native integration with leading smart glasses such as Rokid, RayNeo and Viture, as it advances its software-defined platform for next-generation human-machine interaction.

To view the full press release, visit https://ibn.fm/uIhVo

Wearable Devices Ltd. (NASDAQ: WLDS) is a growth-stage technology company pioneering the next generation of human-computer interaction through AI-powered neural input wearables. Mudra, its proprietary wrist-worn technology, enables touchless, gesture-based control of digital devices, offering users a seamless, intuitive interface through subtle finger and hand movements. Since introducing its technology to the market in 2014, the company has pursued both business-to-business (B2B) and business-to-consumer (B2C) strategies through a dual-channel model.

The company believes the future of technology should begin with the human. Wearable Devices envisions decoding the human body to enable context-aware AI-powered technology that listens, learns, and adapts – to us.

The company envisions a future where human intent becomes the language of technology. Through non-invasive neural sensing and adaptive algorithms, the company enables more natural, personalized, and intuitive interactions with computers.

The company is headquartered in Yokneam Illit, Israel.

Products

Neural control has entered the market: commercially available since 2023 with the Mudra Band and already used by thousands of users worldwide. With its product line, including Mudra Band and Mudra Link, the company has introduced the world’s first wrist-worn neural interfaces, enabling intuitive, touchless control through natural micro-gestures: subtle finger movements and wrist flicks. Whether streaming media, controlling smart devices, or interacting with AR glasses, Mudra brings neural input into everyday life.

This early adoption isn’t just validation — it’s acceleration. With real users engaging in real environments, the company is learning fast, improving faster, and shaping a product that grows more refined with every interaction.

Mudra Band

Mudra Band is the company’s flagship B2C product, designed as a sleek, aftermarket accessory for the Apple Watch. It uses patented sEMG sensors to detect neural signals from the wrist and translates them into real-time digital commands. This allows users to control and streamline interactions between the iPhone, iPad, MacBook, and Apple TV using familiar micro-gestures like taps, pinches, or swipes — all without touching a screen.

The device features a high-resolution analog front end, IMU integration, adaptive machine learning, and ergonomic form factors for all-day comfort. Users can toggle between multiple Apple devices using the Mudra Band’s dedicated Apple Watch face, enabling a fully connected, touchless experience. The Mudra Band is optimized for low-latency, high-accuracy interactions and supports a wide range of digital applications. The Mudra Band received a CES 2021 Innovation Award.

Mudra Link

Mudra Link expands the company’s reach beyond the Apple ecosystem, offering compatibility with Android, Windows, and AR/XR platforms. The product includes the innovative Gesture Mapper feature, allowing users to assign personalized commands to gestures such as tap, pinch, flick, or twist. This functionality replaces or augments traditional input methods, supporting media controls, pointer input, and full directional mapping. A key feature of Mudra Link is its dual-mode input system (mouse mode or D-pad mode), empowering users to personalize control schemes across devices, operating systems, and user interfaces.

Mudra Link is recognized for its ergonomic design, lightweight build, and plug-and-play ease of use. It supports native integration with AR glasses from leading manufacturers and received a CES 2025 Innovation Award.

Mudra DevKit and Integration

In parallel with its consumer devices, Wearable Devices offers a Mudra Developer Kit (MDK) and integration program for enterprise and OEM partners. The MDK includes full-stack tools (hardware bands, SDK, APIs, and sample code) that allow developers and original equipment manufacturers to embed Mudra’s neural sensing capabilities into their own products and applications. For example, an AR headset maker can integrate Mudra’s sensors to enable native hand-gesture input, or a software developer can use Mudra’s API to track user gestures for novel interactions.

The MDK supports both Android and iOS and even provides real-time neural raw signal monitoring for research and prototyping. This B2B offering not only expands Mudra technology into new environments such as industrial automation, robotics, and gaming peripherals, but also fosters a broader ecosystem of Mudra-powered solutions. By lowering the barrier for others to adopt its AI gesture recognition engine, Wearable Devices accelerates innovation and garners strategic relationships.

The MDK and related licensing offerings illustrate Wearable Devices’ push-pull strategy: selling consumer products today, while seeding ‘Mudra inside’ into other companies’ devices tomorrow.

Market Opportunity & Strategy

Wearable Devices operates at the intersection of neural interfaces, wearable computing, and the rapidly expanding AR/XR sector. According to MarketsandMarkets, the global AR and VR market is projected to grow from $22.12 billion in 2024 to $96.32 billion by 2029, at a CAGR of 34.2%. The rising demand for natural, hands-free input methods positions neural wearables like Mudra as foundational components in spatial computing and smart environments.

Additionally, the health monitoring wearables market is gaining traction as neural biosignals become a promising data source. The company’s LMM (Large Motor Unit Action Potential Model) platform is being explored for predictive health monitoring, cognitive state tracking, and performance analytics. Government-level support, such as advocacy from the U.S. Secretary of Health and Human Services, further validates the sector’s momentum.

Combined with patent-protected technology and strategic alliances with companies like Qualcomm, TCL-RayNeo™, and Media Exceed, Wearable Devices is well-positioned to capture value across consumer, enterprise, and healthcare verticals.

The company’s phased market strategy anticipates this:

• Phase 1 – Enthusiast Consumer Adoption: Introduce Mudra Band as an add-on for Apple Watch (tapping into a passionate user base of early adopters and tech enthusiasts). Achieve proof-of-concept and get market feedback. This phase built brand credibility and seeded a community of users.
• Phase 2 – Expand Platform & Ecosystem: Launch Mudra Link for all users and open the Mudra SDK to developers and B2B partners. Focus on the XR/AR market and tech-savvy consumers, while enabling enterprise use-cases through the Developer Kit and strategic partnerships. The company is actively showcasing its tech to industry leaders and integrating with their platforms.
• Phase 3 – Leverage Data & Enter New Verticals: With a growing user base, Wearable Devices is collecting an invaluable dataset of neural signals and usage patterns. If data is the new oil for AI, neural signals will power the next computing revolution — enabling machines to understand human intent in real time. This fuels its Large Motor-Unit Action Potential Model (LMM) – a bio-signal intelligence platform that continuously learns from neural data to improve accuracy and enable new applications. One major new vertical is digital health and wellness: Wearable Devices is adapting its tech to track physiological and cognitive indicators from the wrist. Because the Mudra sensors capture muscle activation signals, they can potentially detect patterns related to stress, fatigue, focus, and even early signs of health conditions before traditional symptoms appear, and Wearable Devices recently announced it is expanding LMM into predictive health monitoring and cognitive analytics. This means the company could offer solutions for workplace productivity (measuring alertness), athletic training (muscle fatigue analytics), or preventive healthcare (flagging neuromuscular irregularities) – vastly broadening its addressable market. Through monitor applications, the vision is to go from controlling devices to also understanding the user, providing actionable bio-insights. The LMM platform’s AI continuously adapts to each individual’s neural profile, enabling truly personalized and proactive applications.
• Phase 4 – Ubiquitous Adoption via B2B Integration: Finally, Wearable Devices plans to drive mass adoption by aligning with major consumer tech players. By making its Mudra Data Platform available to enterprises, OEMs, and app developers, the company positions itself as the backbone for neural interaction services. By “laying the groundwork for the next neural frontier”, Wearable Devices is ensuring that when the tech giants move to adopt neural input, its platform is the mature, data-rich standard ready to be deployed.

Through these phased efforts, Wearable Devices balances B2C and B2B paths. It generates near-term revenues and user feedback via direct consumer product sales, while simultaneously developing long-term enterprise relationships and intellectual property value. This dual model not only diversifies revenue streams but also reinforces the technology’s credibility: consumer adoption demonstrates demand and usability, which in turn attracts enterprise interest, creating a virtuous cycle.

Leadership Team

Asher Dahan, Chief Executive Officer, co-founded Wearable Devices Ltd. in 2014 and has served as CEO and director since 2016. He is a seasoned executive with proven expertise in strategic planning, project execution, and business leadership. Asher oversees the company’s operations and resources, guiding major corporate decisions and long-term vision. Prior to founding Wearable Devices, he held engineering and leadership roles at Intel Haifa, specializing in high-speed interface validation. He holds a BSc in Electrical Engineering from Ort Braude College.

Guy Wagner, Chief Scientific Officer and President, co-founded Wearable Devices Ltd. in 2014 and has served on its board since inception. As CSO and President, Guy leads the company’s technological innovation and scientific direction. He is the main inventor behind the company’s core technology and brings multidisciplinary expertise in hardware design, biomedical signal processing, embedded programming, and sensor systems. He previously worked at Intel as a hardware engineer and holds a BSc in Electrical Engineering from Ort Braude College.

Leeor Langer, co-founder and CTO since 2016, is a leading expert in algorithms, machine learning, and signal and image processing. He has held senior R&D roles in the medical imaging and digital security sectors, including at Intel, and brings deep academic and industry experience. Leeor has authored several scientific papers and holds a BSc from the Technion and an MSc in Applied Mathematics from Tel Aviv University, graduating cum laude.

Wearable Devices Ltd. (NASDAQ: WLDS), closed Monday's trading session at $0.75, off by 1.5619%, on 123,895 volume. The average volume for the last 3 months is 227,272 and the stock's 52-week low/high is $0.7407/$11.3999.

Recent News

• Wearable Devices Ltd. (NASDAQ: WLDS) - TechMediaBreaks - Wearable Devices Ltd. (NASDAQ: WLDS) to Debut Mudra Experience Studio at MWC Barcelona 2026
• TechMediaBreaks - Wearable Devices Ltd. (NASDAQ: WLDS) Launches ai6 Labs Neural AI Ecosystem to Bridge Human Intent and Digital Reality
• AINewsBreaks - Wearable Devices Ltd. (NASDAQ: WLDS) Featured in AINewsWire Editorial on Next Wave of AI Investment